2022
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.Peer-Reviewed Original ResearchConceptsThrombopoietin receptor agonistsChronic immune thrombocytopeniaSecond-line therapyImmune thrombocytopeniaEarly useCurrent practice trendsProbabilistic sensitivity analysesCost-effective treatmentFirst cost-effectiveness analysisCost-effectiveness analysisU.S. health systemLack of evidenceEarly splenectomyHematology (ASH) guidelinesReceptor agonistCurrent guidelinesSplenectomyClinical practicePractice trendsTherapyHealth systemCost-effective strategyRituximabThrombocytopeniaAmerican Society
2021
Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia
Goshua G, Sinha P, Pischel L, Lee A, Cuker A. Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia. Blood 2021, 138: 751. DOI: 10.1182/blood-2021-144819.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioChronic immune thrombocytopeniaOne-way deterministic sensitivity analysisPost-splenectomy sepsisTPO-RATPO-RA therapyImmune thrombocytopeniaOverall response rateTreatment pathwaysProbabilistic sensitivity analysesDeterministic sensitivity analysesResponse rateAdverse eventsASH guidelinesStandard second-line treatment optionSecond-line treatment optionSecond-line treatment strategiesEarly useComplete response rateSecond-line therapySevere septic shockThrombopoietin receptor agonistsSeptic shock mortalityHealth system perspectiveCost of surgery